A number of other research firms also recently issued reports on GSK. Deutsche Bank reiterated a hold rating on shares of GlaxoSmithKline in a report on Thursday, October 31st. New Street Research raised GlaxoSmithKline from a reduce rating to a hold rating in a research report on Wednesday, October 16th. Jefferies Financial Group reissued a buy rating on shares of GlaxoSmithKline in a research report on Thursday, August 29th. UBS Group reissued a neutral rating on shares of GlaxoSmithKline in a research report on Wednesday, October 23rd. Finally, JPMorgan Chase & Co. reissued a neutral rating on shares of GlaxoSmithKline in a research report on Thursday, October 17th. One equities research analyst has rated the stock with a sell rating, fourteen have given a hold rating and four have given a buy rating to the stock. The company currently has a consensus rating of Hold and a consensus target price of $41.79.
NYSE:GSK opened at $44.42 on Wednesday. The company has a debt-to-equity ratio of 1.38, a quick ratio of 0.56 and a current ratio of 0.82. The company has a market cap of $110.42 billion, a PE ratio of 14.06, a PEG ratio of 3.03 and a beta of 0.70. GlaxoSmithKline has a 52-week low of $36.41 and a 52-week high of $46.01. The stock has a 50-day simple moving average of $42.96 and a 200 day simple moving average of $41.12.
In related news, Director Plc Glaxosmithkline purchased 177,777 shares of GlaxoSmithKline stock in a transaction that occurred on Tuesday, September 10th. The stock was purchased at an average cost of $45.00 per share, with a total value of $7,999,965.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 10.00% of the company’s stock.
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Prime Capital Investment Advisors LLC acquired a new stake in shares of GlaxoSmithKline in the third quarter valued at approximately $26,000. Prestige Wealth Management Group LLC acquired a new stake in shares of GlaxoSmithKline in the second quarter valued at approximately $26,000. Berman Capital Advisors LLC lifted its position in shares of GlaxoSmithKline by 58.1% in the second quarter. Berman Capital Advisors LLC now owns 656 shares of the pharmaceutical company’s stock valued at $26,000 after buying an additional 241 shares during the last quarter. Financial Gravity Wealth Inc. lifted its position in shares of GlaxoSmithKline by 62.7% in the second quarter. Financial Gravity Wealth Inc. now owns 799 shares of the pharmaceutical company’s stock valued at $32,000 after buying an additional 308 shares during the last quarter. Finally, Manchester Financial Inc. acquired a new stake in shares of GlaxoSmithKline in the second quarter valued at approximately $39,000. 11.19% of the stock is owned by institutional investors.
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.
Further Reading: Is it better to buy a fund with a higher or lower NAV?
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.